These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 18076811)

  • 1. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
    Huang JJ; Lin TY
    Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B; Hidalgo M
    Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
    Bjelogrlić SK; Srdić T; Radulović S
    J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of mTOR in the management of solid tumors: an overview.
    Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
    Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
    Brachmann S; Fritsch C; Maira SM; García-Echeverría C
    Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.
    Costa LJ
    Cancer Treat Rev; 2007 Feb; 33(1):78-84. PubMed ID: 17161912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E; Salvadori M
    J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of mTOR inhibitors in non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A
    Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.
    Georgakis GV; Younes A
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):131-40. PubMed ID: 16375650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biology behind mTOR inhibition in sarcoma.
    Wan X; Helman LJ
    Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Topics in mTOR pathway and its inhibitors].
    Dreyer C; Sablin MP; Faivre S; Raymond E
    Bull Cancer; 2009 Jan; 96(1):87-94. PubMed ID: 19211363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
    Huang S; Houghton PJ
    Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.
    Panner A; Parsa AT; Pieper RO
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1313-22. PubMed ID: 17020463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [mTOR inhibitor].
    Muro K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An expanding role for mTOR in cancer.
    Guertin DA; Sabatini DM
    Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IRS-1: auditing the effectiveness of mTOR inhibitors.
    Easton JB; Kurmasheva RT; Houghton PJ
    Cancer Cell; 2006 Mar; 9(3):153-5. PubMed ID: 16530700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
    Janus A; Robak T; Smolewski P
    Cell Mol Biol Lett; 2005; 10(3):479-98. PubMed ID: 16217558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the role of mTOR in cancer.
    Guertin DA; Sabatini DM
    Cancer Cell; 2007 Jul; 12(1):9-22. PubMed ID: 17613433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the mTOR pathway using deforolimus in cancer therapy.
    Mahalingam D; Sankhala K; Mita A; Giles FJ; Mita MM
    Future Oncol; 2009 Apr; 5(3):291-303. PubMed ID: 19374536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.